Am J Health Syst Pharm. 2010;67(3):193-205. Significant pharmacokinetic interactions were observed when etravirine was used in combination with tipranavir-ritonavir, fosamprenavir-ritonavir, and ...

Massachusetts Institute of Technology has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding agent coupled to cyclin-dependent kinase 9 (CDK9)-targeting ...

The University of Michigan has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to signal transducer and activator of transcription 3 (STAT3)-targeting ...

Avoid concomitant use of REZLIDHIA with strong or moderate CYP3A inducers. Avoid concomitant use of REZLIDHIA with sensitive CYP3A substrates unless otherwise instructed in the substrates ...

Avoid concomitant use of REZLIDHIA with strong or moderate CYP3A inducers. Avoid concomitant use of REZLIDHIA with sensitive CYP3A substrates unless otherwise instructed in the substrates prescribing ...

The numerous drug interactions with cytochrome P-450 (CYP) isoenzyme inducers and inhibitors, as well as the possibility of liver toxicity, especially in patients with hepatitis or elevated ...